Induction of Antigen Specific Immunological Tolerance Using Inducible Pluripotent Stem Cell Derived Veto Cells
US-2024374723-A1 · Nov 14, 2024 · US
HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
US9567566B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9567566-B2 |
| Application number | US-201213533492-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 26, 2012 |
| Priority date | Jul 25, 2008 |
| Publication date | Feb 14, 2017 |
| Grant date | Feb 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of enhancing an antigen-specific immune response in a host comprising administering to the host: (i) an antigen and (ii) a polypeptide comprising Nsbp1 (SEQ ID NO: 5), in an amount effective to enhance an antigen-specific immune response. 2. A method of enhancing the activation or recruitment of dendritic cells in a host comprising administering to the host: (i) an antigen and (ii) a polypeptide comprising Nsbp1 (SEQ ID NO: 5), in an amount effective to enhance the activation and recruitment of dendritic cells in the host. 3. A method of shifting the Th-1/Th-2 balance of an immune response of a host towards a Th-1 type immune response comprising administering to the host (i) an antigen or nucleic acid encoding same, and (ii) a polypeptide comprising Nsbp1 (SEQ ID NO: 5), in an amount effective to shift the Th-1/Th-2 balance of an immune response towards a Th-1 type immune response. 4. The method of claim 1 , wherein the method comprises administering two or more different antigens to the host. 5. The method of claim 1 , wherein the antigen is a tumor antigen. 6. The method of claim 5 , wherein the tumor antigen is a melanoma antigen. 7. The method of claim 1 , wherein the method comprises administering a nucleic acid encoding the antigen. 8. The method of claim 1 , wherein the host is a human. 9. The method of claim 2 , wherein the antigen is a tumor antigen. 10. The method of claim 3 , wherein the antigen is a tumor antigen. 11. The method of claim 9 , wherein the tumor antigen is a melanoma antigen. 12. The method of claim 10 , wherein the tumor antigen is a melanoma antigen. 13. The method of claim 2 , wherein the method comprises administering two or more different antigens to the host.
Assignees
Inventors
Classifications
from mammals · CPC title
Bacillus · CPC title
characterised by the type of response, e.g. Th1, Th2 · CPC title
Adjuvants · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9567566B2 cover?
- A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1…
- Who is the assignee on this patent?
- Yang De, Oppenheim Joost J, Bustin Michael, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0639. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).